Clinical Trial Update: Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating reduced doses of an antimony-based therapy with GM-CSF for cutaneous leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• GM-CSF (sargramostim) (granulocyte-monocyte colony-stimulating factor)
• Sodium stibogluconate (antimony-based) (sodium stibogluconate)

Snippet

Sponsor: Hospital Universitário Professor Edgard Santos | Conditions: Cutaneous Leishmaniasis | Phase 2 | Status: COMPLETED